BMY gets a priority FDA review for Opdivo's use in previously untreated advanced Hodgkin lymphoma, reinforcing its oncology ...

US FDA Grants Priority Review to Bristol Myers Squibb's Application for Opdivo (nivolumab) Plus Chemotherapy Combination for Classic Hodgkin Lymphoma ...

US pharma major Bristol Myers Squibb has announced progress for its multi-indication cancer drug Opdivo (nivolumab) in ...

Bristol Myers Squibb Canada (BMS) is pleased to announce that OPDIVO® SC (nivolumab for subcutaneous injection) is now included on the Liste des Médicaments-Établissements. Quebec is the first ...

U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma, by Bristol ...

Based on phase 3 trial data, the FDA accepted an sBLA for nivolumab plus AVD for untreated stage III or IV classical Hodgkin lymphoma.

The global Merkel Cell Carcinoma (MCC) market is rapidly evolving, driven by advancements in immunotherapy and a surge in early diagnoses. Merkel cell carcinoma, a rare, aggressive skin cancer mainly ...

Diakonos Oncology has received more than $7 million from the Cancer Prevention and Research Institute of Texas to support a ...

The immunotherapies used to treat melanoma now include well-established drugs such as Keytruda (pembrolizumab) and Opdivo (nivolumab) and newer ones such as Amtagvi (lifileucel), which uses T cells ...

During a live event, Moshe C. Ornstein, MD, MA, discussed the recommended regimens for non–clear cell renal cell carcinoma ...

Merge Americas announced the first keynote speakers confirmed for the 12th annual eMerge Americas Conference + Expo, the premier global technology conference and expo shaping the future of tech, ...

Arcus Biosciences (RCUS) stock falls as the company and partner Gilead (GILD) halt a Phase 3 cancer trial evaluating its anti ...